3′-Stabilized Modified RNA for Longer Half-Life and Protein Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
mRNA therapeutics face challenges of instability, toxicity, short-term efficacy, and potential immunological responses, limiting their feasibility for clinical applications.
Innovation Solution
The development of RNA molecules with a 3′-stabilizing region covalently linked via a linker, incorporating purification handles, which are selectively attached to full-length precursor RNA during purification, enhancing stability and translation efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If chemical modifications are introduced into mRNA to increase stability, then mRNA half-life is improved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent applies parameter changes by modifying the poly-A tail composition - specifically incorporating non-canonical nucleotides (such as inosine, 2'-O-methyladenosine) and varying the tail length (e.g., 100-250 residues) to optimize mRNA stability without requiring complex chemical modification protocols throughout the entire mRNA structure
Solution Approach 2:
The patent applies local quality by introducing modifications specifically at the 3' end poly-A tail region rather than throughout the entire mRNA molecule. This localized approach targets the degradation-prone area while maintaining simplicity in the coding and 5' regions, thus improving stability with minimal increase in manufacturing complexity
2Reliability
If high dose or repeated administration is used to overcome mRNA degradation, then therapeutic efficacy is improved, but immunogenicity and toxicity increase
Solution Approach 1:
The patent applies preliminary action by pre-stabilizing the mRNA molecule through optimized poly-A tail design (incorporating non-canonical nucleotides and specific lengths) before administration. This preliminary stabilization ensures the mRNA survives long enough in vivo to achieve therapeutic effect at lower doses, avoiding the need for repeated high-dose administrations that trigger immunogenicity
Solution Approach 2:
The patent effectively creates a more durable mRNA construct that acts as a 'longer-lasting' therapeutic agent. By extending functional half-life through poly-A tail optimization, a single administration can achieve sustained protein expression, replacing the need for multiple short-lived dosing regimens that accumulate immunogenic effects
3Productivity
If poly-A tail length is increased to improve translation efficiency, then protein expression is improved, but mRNA susceptibility to 3'-exonucleases increases
Solution Approach 1:
The patent applies parameter changes by altering the chemical composition of the poly-A tail - incorporating non-canonical nucleotides (inosine, 2'-O-methyladenosine, pseudouridine) instead of solely canonical adenosine. This compositional change allows the tail to maintain sufficient length (100-250 residues) for translation efficiency while the modified nucleotides confer resistance to 3'-exonuclease degradation
Solution Approach 2:
The patent applies composite materials by creating a hybrid poly-A tail structure that combines canonical adenosine residues with non-canonical nucleotide modifications. This composite composition provides both the functional properties needed for translation (sufficient length and structure) and enhanced stability (resistance to exonucleases), resolving the contradiction between length and stability
Data Source
AI summary
Described herein are modified RNA molecules where a 3′-stabilizing region is covalently attached to the RNA, and where the 3′-stabilizing region comprises one or more modified nucleosides. Methods of synthesizing said RNAs are also provided herein.